Coronary artery disease in HIV infected patients

Escaut, Lelia; Monsuez, Jean Jacques; Chironi, Gilles; Merad, Mansouriah; Teicher, Elina; Smadja, Denis; Simon, Alain; Vittecoq, Daniel
June 2003
Intensive Care Medicine;Jun2003, Vol. 29 Issue 6, p969
Academic Journal
journal article
Objective: To assess the incidence, clinical features, treatment, and follow-up of coronary events in HIV-infected patients over a period of 5 years.Patients and Participants: A cohort of 840 patients.Measurements and Results: A coronary event occurred in 17 patients (5.9/1000 persons-years). Sixteen of them were exposed to highly active antiretroviral therapy (HAART). Patients with coronary events differed in age (48.3 vs. 43 years), CD4 T-cell count (284 vs. 486/mm(3)), total cholesterol (6.2 vs. 5.3 mmol/l), HDL cholesterol (0.72 vs. 1.16 mmol/l), and LDL cholesterol (4.95 vs. 3.391.61 mmol/l). No difference was observed regarding duration of HAART, weight, glucose level, or smoking status between the two groups. Acute coronary syndrome was the first manifestation in 14 patients. Coronary angiography showed 2.56 stenosis per patient, with a single vessel involvement in one-half. Percutaneous angioplasty was performed in all cases, with stenting in 11. After a mean follow-up of 36 months, 14 patients remain alive. Restenosis ( n=4) occurred in 3 patients (PTCA 3; stenting 4). All 14 patients are free of heart failure symptoms. Their mean left ventricular ejection fraction is 61%.Conclusions: A higher coronary-event rate is observed among HIV-infected patients, associated with drug-induced metabolic disturbances and a high prevalence of tobacco smoking. However, treatment and prognosis of acute myocardial infarction has no specificity.


Related Articles

  • Bacterial Pneumonia among HIV-Infected Patients: Decreased Risk After Tobacco Smoking Cessation. ANRS CO3 Aquitaine Cohort, 2000-2007. Bénard, Antoine; Mercié, Patrick; Alioum, Ahmadou; Bonnet, Fabrice; Lazaro, Estibaliz; Dupon, Michel; Neau, Didier; Dabis, François; Chêne, Geneviève // PLoS ONE;2010, Vol. 5 Issue 1, p1 

    Background: Bacterial pneumonia is still a substantial cause of morbidity and mortality in HIV-infected patients in the era of combination Antiretroviral Therapy. The benefit of tobacco withdrawal on the risk of bacterial pneumonia has not been quantified in such populations, exposed to other...

  • Atazanavir: New Option for Treatment of HIV Infection. Havlir, Diane V.; O'marro, Steven D. // Clinical Infectious Diseases;6/1/2004, Vol. 38 Issue 11, p1599 

    Atazanavir is a recently approved human immunodeficiency virus (HIV) protease inhibitor that has an important role in the treatment of both antiretroviral-naive and antiretroviral-experienced individuals. Atazanavir (400 mg) can be administered once per day and requires only 2 capsules. Drug...

  • Dyslipidemia among HIV-infected Patients with Tuberculosis Taking Once-daily Nonnucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in India. Padmapriyadarsini, Chandrasekaran; Kumar, S. Ramesh; Terrin, Norma; Narendran, Gopalan; Menon, Pradeep A.; Ramachandran, Geetha; Subramanyan, Sudha; Venkatesan, Perumal; Wanke, Christine; Swaminathan, Soumya // Clinical Infectious Diseases;2/15/2011, Vol. 52 Issue 4, p540 

    Background. Our aim was to study the incidence and pattern of dyslipidemia among human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB) who received once-daily antiretroviral therapy (ART). Methods. Antiretroviral-naive HIV-infected patients with TB were recruited to a trial...

  • Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Bergersen, B. M.; Sandvik, L.; Bruun, J. N.; Tonstad, S. // European Journal of Clinical Microbiology & Infectious Diseases;Aug2004, Vol. 23 Issue 8, p625 

    Highly active antiretroviral therapy (HAART) may induce dyslipidemia and thus increase the risk of future cardiovascular heart disease (CHD). In this cross-sectional study performed in 2000–2001, the prevalence of a Framingham CHD risk score of >20% in HIV-positive individuals treated or...

  • Concurrent Use of Antiretrovirals and Anticonvulsants in Human Immunodeficiency Virus (HIV) Seropositive Patients. Romanelli, Frank; Pomeroy, Claire // Current Pharmaceutical Design;Jul2003, Vol. 9 Issue 18, p1433 

    Seizure disorders may complicate HIV disease, either as a direct result of HIV or as a manifestation of a secondary opportunistic infection. Unless a reversible cause of seizure activity can be discerned, current treatment guidelines recommend the use of anticonvulsant drugs in these patients....

  • The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa. Ataher, Quazi; Portsmouth, Simon; Napolitano, Laura A.; Eng, Sybil; Greenacre, Anna; Kambugu, Andrew; Wood, Robin; Badal-Faesen, Sharlaa; Tressler, Randy // Journal of the International AIDS Society;2012, Vol. 15 Issue 1, p1 

    Background: The introduction of C-C chemokine receptor type-5 (CCR5) antagonists as antiretroviral therapy has led to the need to study HIV co-receptor tropism in different HIV-1 subtypes and geographical locations. This study was undertaken to evaluate HIV-1 co-receptor tropism in the...

  • The pharmacogenomics of HIV therapy. Pirmohamed, M.; Back, D.J. // Pharmacogenomics Journal;2001, Vol. 1 Issue 4, p243 

    Examines the potential areas where pharmacogenomics of HIV therapy may be of use in maximizing the efficacy and minimizing the toxicity of antiretrovirals. Classes of licensed antiretrovirals; Need for HIV patients to commence therapy with a highly active antiretroviral therapy regimen;...

  • VIRAL IMMUNITY: IFN-γ embargo. Buckland, Jenny // Nature Reviews Immunology;Apr2002, Vol. 2 Issue 4, p221 

    Discusses research being done on the antiviral interferon-γ response of HIV-infected individual. Reference to a study by M.L. Garba and colleagues, published in the 2002 issue of the 'Journal of Immunology'; Factor that caused the reduced interferon-γ responses in suppressors; Significance...

  • Care of treatment-experienced patients with HIV remains an ongoing concern.  // Infectious Disease News;Jul2009, Vol. 22 Issue 7, p14 

    The article discusses research on the use of antiretroviral therapy in treatment-experienced patients with HIV, which was presented at the 2009 American Conference for the Treatment of HIV.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics